

News Article downloaded from - <http://www.bioportfolio.com> on Friday, November 27, 2009
Read [Angiomax Will Retain Decision Resources' Proprietary Clinical Gold Standard Status Over Current and New Therapies, Including Recently-Approved Efiect, for the Treatment of NSTEMI](http://www.bioportfolio.com/news/Angiomax_Will_Retain_Decision_Resources.html) on BioPortfolio.com (http://www.bioportfolio.com/news/Angiomax_Will_Retain_Decision_Resources.html)

Angiomax Will Retain Decision Resources' Proprietary Clinical Gold Standard Status Over Current and New Therapies, Including Recently-Approved Efiect, for the Treatment of NSTEMI

Wednesday 25th of February 2009 10:32

BioPortfolio no longer holds the full text of this article in PDF form.

[Click Here To Read BioPortfolio's Web Page on Angiomax Will Retain Decision Resources' Proprietary Clinical Gold Standard Status Over Current and New Therapies, Including Recently-Approved Efiect, for the Treatment of NSTEMI](http://www.bioportfolio.com/news/Angiomax_Will_Retain_Decision_Resources.html)

- [Angiomax Will Retain Decision Resources' Proprietary Clinical Gold ... 25 Feb 2009 ... Angiomax Will Retain Decision Resources' Proprietary Clinical Gold Standard Status Over Current and New Therapies, ...](http://www.reuters.com/article/pressRelease/idUS199318+25-Fe...)
<http://www.reuters.com/article/pressRelease/idUS199318+25-Fe...>
- [reviewjournal.com -- PRESS RELEASES Angiomax Will Retain Decision Resources' Proprietary Clinical Gold Standard Status Over Current and New Therapies, Including Recently-Approved Efiect, ...](http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=LVRJSVY.st...)
<http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=LVRJSVY.st...>
- [Archive News & Video for Wednesday, 25 Feb, 2009 | Reuters.com Angiomax Will Retain Decision Resources' Proprietary Clinical Gold Standard Status... 10:32 AM EST. Research and Markets: All Major Investors in Possible](#)
...

<http://www.reuters.com/resources/archive/us/20090225.html...>

Above results from a Google Custom Search Engine. [Search on BioPortfolio](#)
Via PR Newswire - PRNewswire.co.uk

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472
[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.
BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road,
Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10
Copyright 1997-2009 - BioPortfolio Limited.

